These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29455596)

  • 21. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
    Sulman EP; Ismaila N; Armstrong TS; Tsien C; Batchelor TT; Cloughesy T; Galanis E; Gilbert M; Gondi V; Lovely M; Mehta M; Mumber MP; Sloan A; Chang SM
    J Clin Oncol; 2017 Jan; 35(3):361-369. PubMed ID: 27893327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
    Rudin CM; Ismaila N; Hann CL; Malhotra N; Movsas B; Norris K; Pietanza MC; Ramalingam SS; Turrisi AT; Giaccone G
    J Clin Oncol; 2015 Dec; 33(34):4106-11. PubMed ID: 26351333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer.
    Lim HY; Agarwal AM; Agarwal N; Ward JH
    Singapore Med J; 2009 May; 50(5):e178-80. PubMed ID: 19495504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.
    Rago R
    Cancer Control; 1998 Nov; 5(6):513-521. PubMed ID: 10761100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
    Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
    BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Update on current care guideline: prostate cancer].
    Duodecim; 2014; 130(16):1666-7. PubMed ID: 25269372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
    Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Megestrol acetate in the treatment of metastatic carcinoma of the prostate.
    Venner P
    Oncology; 1992; 49 Suppl 2():22-7. PubMed ID: 1461622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of progressive metastatic prostate cancer.
    Waselenko JK; Dawson NA
    Oncology (Williston Park); 1997 Oct; 11(10):1551-60; discussion 1560-3, 1567-8. PubMed ID: 9348559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary.
    J Oncol Pract; 2009 May; 5(3):127-129. PubMed ID: 29452038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical practice guideline (update): adult sinusitis.
    Rosenfeld RM; Piccirillo JF; Chandrasekhar SS; Brook I; Ashok Kumar K; Kramper M; Orlandi RR; Palmer JN; Patel ZM; Peters A; Walsh SA; Corrigan MD
    Otolaryngol Head Neck Surg; 2015 Apr; 152(2 Suppl):S1-S39. PubMed ID: 25832968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Sharifi N; Dahut WL; Figg WD
    BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient.
    Beekman KW; Hussain M
    Urol Oncol; 2008; 26(4):415-9. PubMed ID: 18593620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.